Back To: Home : Featured Technology : Stem Cell
|
Thrive announces
instruments and services agreement with Harvard Stem Cell Institute
September 2016
SHARING OPTIONS:
WAKEFIELD, Mass.—Recently, Thrive Bioscience, a manufacturer of automated cell culture management systems, and the Harvard Stem
Cell Institute (HSCI) in Cambridge, Mass., announced an agreement under which Thrive will develop instruments for the growth and maintenance of induced
pluripotent stem cells (iPSCs). The agreement includes development of automated iPSC protocols critical to HSCI and its researchers. HSCI plans to utilize
the Thrive systems within the Harvard Stem Cell Institute iPS Core Facility and affiliated research sites.
Terms of the
agreement include HSCI gaining early access to the Thrive Bioscience technology, purchase of multiple Thrive Bioscience systems by HSCI, protocol development
in advanced stem cell applications (including colony sub-cloning in preparation for gene editing) and the production of iPSC-derived normal and disease-state
cell lines. These applications are said to be integral to new, groundbreaking approaches in the discovery of patient therapies and regenerative
medicine.
“This agreement provides Thrive Bioscience the opportunity to develop systems for world-renowned
researchers at Harvard Stem Cell Institute in the highly dynamic and expanding field of stem cell technology,” said the company’s chief
scientific officer and co-founder, Dr. Alan-Philippe Blanchard. “The result is the development of a comprehensive product that meets industry and
researcher needs.”
Back |
|||||||
|
|
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|
© Copyright 2019 Old River Publications LLC. All righs reserved. | Web site managed and designed by OffWhite.